| Market Cap | 554.25M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -75.55M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -14.00% |
| Sales | 1.65M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -24.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -60.00% |
| Recommedations | - | Quick Ratio | 0.05 | Shares Outstanding | 1.25B | 52W Low Chg | 13.00% |
| Insider Own | 8.88% | ROA | -137.16% | Shares Float | 1.14B | Beta | -0.59 |
| Inst Own | 0.05% | ROE | - | Shares Shorted/Prior | 14.14M/13.83M | Price | 0.51 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,414,462 | Target Price | - |
| Oper. Margin | -3,424.31% | Earnings Date | Nov 7 | Volume | 2,452,201 | Change | -2.38% |
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
| Oppenheimer | Perform | Mar 12, 14 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MALIK NAVID | Director Director | Nov 16 | Sell | 0.83 | 570,000 | 473,100 | 12/01/23 |